Andrea Carfi

Dr. Andrea Carfi


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2020 in Nature
Verified
Journal Article
Closed access
PDF file
KCKizzmekia S. Corbett
Kizzmekia S. Corbett
DEDarin K. Edwards
Darin K. Edwards
SLSarah R. Leist
Sarah R. Leist
OAOlubukola M. Abiona
Olubukola M. Abiona
SBSeyhan Boyoglu-Barnum
Seyhan Boyoglu-Barnum
BGBarney S. Graham
Barney S. Graham

1 July 2001 in Molecular Cell
Verified
Journal Article
Closed access
ACAndrea Carfi
Andrea Carfi
SWSharon H. Willis
Sharon H. Willis
JWJ.CHarles Whitbeck
J.CHarles Whitbeck
Claude KrummenacherClaude Krummenacher
Claude Krummenacher
GCGary H. Cohen
Gary H. Cohen
DWDon C. Wiley
Don C. Wiley

1 November 1998 in Molecular Cell
Verified
Journal Article
Closed access
WWWinfried Weissenhorn
Winfried Weissenhorn
ACAndrea Carfi
Andrea Carfi
KLKon-Ho Lee
Kon-Ho Lee
JSJohn J. Skehel
John J. Skehel
DWDon C. Wiley
Don C. Wiley

18 March 2021 in Cell
Verified
Journal Article
Closed access
MGMakda Gebre
Makda Gebre
LBLuis A. Brito
Luis A. Brito
LTLisa H. Tostanoski
Lisa H. Tostanoski
DEDarin K. Edwards
Darin K. Edwards
ACAndrea Carfi
Andrea Carfi
DBDan H. Barouch
Dan H. Barouch

17 May 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KSKurt A. Swanson
Kurt A. Swanson
ESEthan C. Settembre
Ethan C. Settembre
CSChristine A. Shaw
Christine A. Shaw
ADAntu Dey
Antu Dey
RRRino Rappuoli
Rino Rappuoli
ACAndrea Carfi
Andrea Carfi
Respiratory syncytial virus (RSV), the main cause of infant bronchiolitis, remains a major unmet vaccine need despite more than 40 years of vaccine research. Vaccine candidates based on a chief RSV neutralization antigen, the fusion (F) glycoprotein, have foundered due to problems with stability, purity, reproducibility, and potency. Crystal structures of related parainfluenza F glycoproteins have revealed a large conformational change between the prefusion and postfusion states, suggesting that postfusion F antigens might not efficiently elicit neutralizing antibodies. We have generated a homogeneous, stable, and reproducible postfusion RSV F immunogen that elicits high titers of neutralizing antibodies in immunized animals. The 3.2-Å X-ray crystal structure of this substantially complete RSV F reveals important differences from homology-based structural models. Specifically, the RSV F crystal structure demonstrates the exposure of key neutralizing antibody binding sites on the surface of the postfusion RSV F trimer. This unanticipated structural feature explains the engineered RSV F antigen's efficiency as an immunogen. This work illustrates how structural-based antigen design can guide the rational optimization of candidate vaccine antigens.

17 November 2005 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
Claude KrummenacherClaude Krummenacher
Claude Krummenacher
VSVinit M Supekar
Vinit M Supekar
JWJ Charles Whitbeck
J Charles Whitbeck
ELEric Lazear
Eric Lazear
SCSarah A Connolly
Sarah A Connolly
ACAndrea Carfi
Andrea Carfi
Herpes simplex virus (HSV) entry into cells requires binding of the envelope glycoprotein D (gD) to one of several cell surface receptors. The 50 C‐terminal residues of the gD ectodomain are essential for virus entry, but not for receptor binding. We have determined the structure of an unliganded gD molecule that includes these C‐terminal residues. The structure reveals that the C‐terminus is anchored near the N‐terminal region and masks receptor‐binding sites. Locking the C‐terminus in the position observed in the crystals by an intramolecular disulfide bond abolished receptor binding and virus entry, demonstrating that this region of gD moves upon receptor binding. Similarly, a point mutant that would destabilize the C‐terminus structure was nonfunctional for entry, despite increased affinity for receptors. We propose that a controlled displacement of the gD C‐terminus upon receptor binding is an essential feature of HSV entry, ensuring the timely activation of membrane fusion.